An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse

Inclusion Criteria:

- Provision of Informed consent

- Subjects must have been enrolled in and have met the inclusion/exclusion criteria of
the MORAb-003-002 study.

- Subjects must have achieved a normalization of CA 125 levels and/or CR or PR (or
stable disease and an investigator's assessment of a clinical benefit) after
MORAb-003 in combination with standard chemotherapy and have not yet met the criteria
for disease progression during participation in the MORAb-003-002 study.

- Subjects must be currently receiving single-agent MORAb-003 maintenance therapy.

Exclusion Criteria:

- Subjects that discontinued the MORAb-003-002 study for any reason.